Michael Stokes, Ph.D., is a passionate research scientist dedicated to bringing new therapies to patients. At HiberCell, Michael’s focus is on understanding how ER stress signaling enables cancer cell proliferation, and how these pathways can be targeted to disrupt hard-to-treat tumors.
Prior to joining HiberCell, Michael conducted postdoctoral research at Columbia University. During this time, he led a multidisciplinary research effort to develop novel selective inhibitors of MYCN-driven tumors. Michael has won several awards for his research, which have resulted in two patent applications and nine peer-reviewed publications.
Michael received an H.B.Sc. from the University of Western Ontario and completed his Ph.D. in the department of Cell & Systems Biology at the University of Toronto.